New liver safety study for experimental drug MDR-001 begins
NCT ID NCT07550634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study will give a single dose of MDR-001, a GLP-1 receptor agonist tablet, to 32 people: some with mild or moderate liver impairment and some with healthy livers. Researchers want to see how the drug moves through the body and if it is safe in people with liver issues. The goal is to gather information, not to treat the liver condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MDR-001 (a GLP-1 receptor agonist tablet)
- What this could lead to
- If successful, this study could help doctors understand how to safely dose MDR-001 in patients with liver problems.
- What could go wrong
- This is a very early Phase 1 trial with only 32 participants. It is designed to measure drug levels and safety, not to treat liver disease. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (MILD AND MODERATE, CHILD-PUGH CLASS A AND B) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.